Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 5, 2015, Pages 1027-1028

  Leiva Salinas, M ^a   Frances L ^a   Marin Cabanas, I ^a   Arribas Granados, M P ^a   Silvestre, J F ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; MONTELUKAST; OMALIZUMAB; PEGINTERFERON ALPHA; PEGYLATED INTERFERON ALPHA 2A; RIBAVIRIN; STEROID; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ANGIONEUROTIC EDEMA; CASE REPORT; CHRONIC URTICARIA; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; LETTER; MIDDLE AGED; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; COMPLICATION; URTICARIA;

ANTI-ALLERGIC AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MIDDLE AGED; OMALIZUMAB; URTICARIA;

EID: 84928369264     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12450     Document Type: Letter

References (10)

1. Zuberbier T, Asero R, Bindslev-Jensen C, et al.,. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. Zuberbier T, Asero R, Bindslev-Jensen C, et al.,. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
3. Maurer M, Magerl M, Metz M, Zuberbier T,. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2013. doi: 10.1111/ddg.12194. [Epub ahead of print].
4. Cribier B,. Urticaria and hepatitis. Clin Rev Allergy Immunol 2006; 30: 25-29.
5. Siddique N, Pereira BN, Hasan Arshad S,. Hepatitis C and urticaria: cause and effect? Allergy 2004; 59: 668.
6. Cribier BJ, Santinelli F, Schmitt C, Stoll-Keller F, Grosshans E,. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: a case-control study. Arch Dermatol 1999; 135: 1335-1339.
7. Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, et al.,. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther 2013; 26: 257-259.
8. Maurer M, Rosen K, Hsieh HJ,. Omalizumab for chronic urticaria. N Engl J Med 2013; 368: 2530.
9. Maurer M, Altrichter S, Bieber T, et al.,. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin Immunol. 2011; 128: 202-209.
10. Antonicelli L, Stagnozzi G, Giuliodoro S, et al.,. The safety of omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C. Ann Allergy Asthma Immunol 2009; 103: 269-270.